The PPAR Gamma Agonist Troglitazone Regulates Erk 1/2 Phosphorylation via a PPARγ-Independent, MEK-Dependent Pathway in Human Prostate Cancer Cells. (20th February 2012)

• Record Type: Journal Article
• Authors: Bolden, Adrienne; Bernard, Lynikka; Jones, Danielle; Akinyeke, Tunde; Stewart, LaMonica V.
• Other Names: Phipps R. P. Academic Editor.
• Is Part Of: PPAR research. Volume 2012(2012)
• Publication Date: 2012-02-20
• Subjects: Peroxisomes -- Periodicals; Peroxisomal disorders -- Periodicals; 571.65505
• DOI: 10.1155/2012/929052
• Languages: English
• ISSNs: 1687-4757

Abstract

Abstract : Thiazolidinediones (TZDs) dramatically reduce the growth of human prostate cancer cells in vitro and in vivo . To determine whether the antitumor effects of TZDs were due in part to changes in the MEK/Erk signaling pathway, we examined the regulation of Erk phosphorylation by the TZD troglitazone within the PC-3 and C4-2 human prostate cancer cell lines. Western blot analysis revealed troglitazone-induced phosphorylation of Erk in both PC-3 and C4-2 cells. Troglitazone-induced increases in Erk phosphorylation were suppressed by the MEK inhibitor U0126 but not by the PPARγ antagonist GW9662. Pretreatment with U0126 did not alter the ability of troglitazone to regulate expression of two proteins that control cell cycle, p21, and c-Myc. Troglitazone was also still effective at reducing PC-3 proliferation in the presence of U0126. Therefore, our data suggest that troglitazone-induced Erk phosphorylation does not significantly contribute to the antiproliferative effect of troglitazone.